| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Ascendis Pharma A/S | 16 | Q3 2019 | 18.3% |
| BioCryst Pharmaceuticals Inc | 15 | Q3 2019 | 20.9% |
| Ra Pharmaceuticals | 12 | Q3 2019 | 6.4% |
| Biohaven Pharmaceuticals | 11 | Q4 2019 | 18.1% |
| Obseva SA | 11 | Q4 2019 | 12.2% |
| DBV Technologies | 10 | Q1 2018 | 11.6% |
| Kalvista Pharmaceuticals | 10 | Q4 2019 | 6.4% |
| Bellerophon Therapeutics | 10 | Q4 2019 | 3.0% |
| AveXis Inc | 9 | Q1 2018 | 32.2% |
| Edge Therapeutics Inc | 9 | Q4 2017 | 18.2% |
View VHCP Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-10-26 |
| 4 | 2022-10-20 |
| 4 | 2022-10-17 |
| 4 | 2022-10-11 |
| 4 | 2022-10-06 |
| 4 | 2022-10-03 |
| 4 | 2022-09-28 |
| 4 | 2022-09-07 |
| 4 | 2022-09-01 |
| 4 | 2022-08-02 |
View VHCP Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.